NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 136 filers reported holding NEKTAR THERAPEUTICS in Q2 2013. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $912,000 | -89.4% | 38,000 | -91.4% | 0.01% | -90.8% |
| Q2 2017 | $8,616,000 | +1741.0% | 440,729 | +2111.5% | 0.08% | +1800.0% |
| Q1 2017 | $468,000 | -53.8% | 19,929 | -75.9% | 0.00% | -55.6% |
| Q4 2016 | $1,014,000 | -14.8% | 82,600 | -23.6% | 0.01% | -40.0% |
| Q1 2015 | $1,190,000 | -69.9% | 108,167 | -57.6% | 0.02% | -70.6% |
| Q4 2014 | $3,954,000 | -38.3% | 255,067 | -51.9% | 0.05% | -46.3% |
| Q3 2014 | $6,404,000 | +2.7% | 530,534 | +9.0% | 0.10% | +2.2% |
| Q2 2014 | $6,237,000 | +49.6% | 486,534 | +41.5% | 0.09% | +31.0% |
| Q1 2014 | $4,169,000 | +57.0% | 343,947 | +47.0% | 0.07% | +57.8% |
| Q4 2013 | $2,656,000 | -35.8% | 233,994 | -41.0% | 0.04% | -41.6% |
| Q3 2013 | $4,139,000 | +269.9% | 396,300 | +309.0% | 0.08% | +250.0% |
| Q2 2013 | $1,119,000 | – | 96,900 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |